[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:myelodysplastic-syndrome:idh2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Myelodysplastic Syndrome","IDH2 Gene",5,[8,16,23,29,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06577441","Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.989103Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06484062","Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes",[20],"Phase 1","2026-08-26T02:16:46.951087Z","2026-05-05T02:43:26.737999Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[20],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.951482Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03383575","Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome",[12],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:26.928444Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03683433","Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",[12],"2026-08-26T02:15:43.339060Z","2026-04-29T02:57:57.075222Z"]